Understanding Burden of Veno-Occlusive Disease (VOD): Comparison of Hospital Stays with Vod Principal Versus Secondary Diagnosis
Author(s)
Aggarwal S1, Topaloglu H2, Kumar S3, Bela A2, Topaloglu O1
1NOVEL Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA, 3NOVEL HEALTH STRATEGIES, COLUMBIA, MD, USA
OBJECTIVES:
To compare hospitalizations with principal and secondary diagnosis of Veno-Occlusive Disease (VOD).
METHODS: The 2016 National Inpatient Sample (NIS) data set from the Healthcare Cost and Utilization Project was utilized in order to analyze hospital admission records for patients with VOD. Three cohorts of patients were designed: Any diagnosis, principal and secondary. Thirty comorbidities were assessed using Elixhauser scoring. Multivariate logistic regression was conducted to assess predictor variables for LOS and costs.
RESULTS:
In 2016, there were an estimated 200 hospitalizations with a diagnosis of VOD, with 35 as principal diagnosis and 165 as secondary. The mean ages in three groups were: 21.1 (SD 21.97), 15.29 (SD 21.48) and 22.33 (SD 22.2) years for any, principal and secondary diagnosis groups, respectively. Nearly half of all VOD patients were covered by Medicaid (48%-Any, 29%-Principal, 52%-Secondary). Majority of the patients in each group were white (43%-Any, 57%-Principal, 39%-Secondary). Interestingly, the mean length of stay was significantly higher in patients with secondary diagnosis (45.35-Any, 20.71-Principal, 50.57-Secondary, p<0.05). The mean hospital charges were also ~3 times higher in the secondary diagnosis group ($1,152,370-Any, $398,930-Principal, $1,312,191-Secondary, p<0.05). The top leading non-VOD principal diagnoses were Acute lymphoblastic leukemia and Acute kidney failure.
CONCLUSIONS: VOD is a serious disorder with very long LOS and high hospital costs. This study shows that patients with secondary diagnosis of VOD incur higher costs than those with principal diagnosis.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
RWD170
Topic
Economic Evaluation
Disease
Rare & Orphan Diseases